Chinanews client, Beijing, February 5th (Reporter Zhang Ni) On the 3rd, the fourth batch of national drug collections that have received much attention announced the results of the proposed selection, and the average price of the selected drugs was reduced by 52%.

It is worth noting that in this round of centralized procurement, the variety of injections has increased significantly, and drugs for the treatment of mental diseases have also been included.

　　According to industry experts, the process of replacing the original research drug market with domestic high-end generic drugs will accelerate in the future. At the same time, domestic pharmaceutical companies are also facing fiercer competition in innovative technologies and industry reshuffle integration.

Data map: Zhejiang Anji automatic medicine dispenser "on duty" photo by Yu Danfei

Centralized drug prices and then "diving" antidepressants included

　　The sharp "diving" of the drug prices to be selected is still the highlight of this centralized procurement.

All 45 drugs included in the procurement were successfully purchased, with an average price reduction of 52%.

　　In this batch of centralized procurement, the prices of many anti-cancer drugs are directly cut in half.

　　For example, the price of a single tablet of the anti-cancer drug Sorafenib dropped from 95 yuan to 30 yuan. Based on the daily consumption of 2 tablets, it can save the patient 3900 yuan per month.

The price of a single injection of bortezomib, an anticancer drug for the treatment of multiple myeloma, has been reduced from 1,500 yuan to 600 yuan, and the entire course of treatment can save about 36,000 yuan.

　　In addition, the gastric ulcer treatment drug esomeprazole enteric-coated tablets (20mg/tablet), the price of each tablet dropped from 9 yuan to 3 yuan after the collection, and the entire treatment course can save about 240 yuan.

　　It is worth mentioning that this centralized procurement included multiple injection varieties for the first time, including 8 injection varieties, which exceeded the sum of the first three batches, and the centralized procurement covered drug dosage form categories further expanded.

The 8 varieties accounted for 31% of the total amount of drugs purchased, with an average price reduction of 75%.

　　Taking ambroxol hydrochloride injection, which is widely used clinically, as an example, the proposed price of Yunnan Longhai Natural Plant Pharmaceutical Co., Ltd.'s product is only 2.3 yuan, and the average price of one piece is only more than 2 cents.

　　Injections are widely used in clinical practice and the dosage is relatively large. The price of multiple injection products included in the centralized procurement has been reduced, which means that the national centralized procurement is further expanding the coverage.

　　In addition, this purchase not only involves drugs for the treatment of hypertension, diabetes, gastrointestinal diseases, malignant tumors, etc., but also drugs for mental diseases, including antidepressants.

　　For example, for the treatment of depression and generalized anxiety disorder, duloxetine hydrochloride enteric-coated capsules were purchased by many domestic pharmaceutical companies’ generic drugs, including Qingdao Baiyang Pharmaceutical Co., Ltd. and Shanghai Shanghai. Zhongxi Pharmaceutical Co., Ltd., CSPC Ouyi Pharmaceutical Co., Ltd., etc.

Data map: The staff of a pharmaceutical company packs drugs.

Gao Zhanshe

Generic drugs accelerate the replacement of the original research drug price and strive for innovation

　　According to news from the National Medical Insurance Administration, a total of 152 companies participated in this centralized procurement, resulting in 118 companies to be selected, and the proportion of companies to be selected increased to 71%.

　　It is worth noting that in this centralized procurement, some multinational pharmaceutical companies also changed their "Buddhist" attitude and actively offered quotations.

　　The 158 products to be selected include 5 products from 5 foreign-funded companies, involving German, French, Indian and Japanese multinational pharmaceutical companies.

　　For example, Fresenius Kabi’s propofol medium/long-chain fat emulsion injection and Sanofi’s amisulpride tablets have both reduced prices by more than 80%, surpassing local pharmaceutical companies.

　　On the other hand, with the implementation of multiple rounds of centralized procurement, the competitive landscape of accelerating the replacement of original research drugs by generic drugs has become increasingly prominent.

　　Among the 158 products to be selected, there are 156 generic drugs that have passed the quality and efficacy consistency evaluation, and 2 original research drugs.

Generic drugs account for an absolute proportion.

　　According to analysis by industry insiders, the main market share of some varieties of this centralized procurement is occupied by original research drugs, and the generic drugs of domestic pharmaceutical companies can quickly grab market share with the help of centralized procurement.

　　At the same time, with the continuous advancement of consistency evaluation, centralized procurement will become a regular sales model for generic drugs, and as product prices decrease, the availability of drugs has further improved, and the rate of product volume has increased significantly.

　　In the context of increasingly fierce domestic generic drug competition, in addition to price, technological innovation is also a key focus of pharmaceutical companies' competition for survival of the fittest.

　　For example, Zheng Aiju, general manager of Baiyang Pharmaceutical, introduced to the media that the duloxetine hydrochloride enteric-coated capsules selected by the company used enteric-coated pellet coating technology (drug-containing layer, isolation layer, enteric layer) , The production process is complex, which poses a great challenge to the pharmaceutical preparation technology, and the technology competition for high-end generic drugs is fierce.

Data map: outpatient building of a hospital.

Photo by China News Agency reporter Yin Liqin

The country's move to "squeeze water" should be an inevitable trend

　　"Group buying", "soul bargaining", the state's move to "squeeze water"... Public opinion often describes the centralized procurement of drugs in this way.

　　Indeed, from the "4+7" centralized procurement pilot to the national expansion, the national "group purchase" of drugs has brought breakthrough results in the past two years: three batches of national centralized procurement of 112 drugs, an average price reduction of 54%, and overall cost savings of more than 100 billion yuan.

　　Before the results of this centralized procurement proposal were announced, the General Office of the State Council had just issued the "Opinions on Promoting the Normalized and Institutionalized Development of Centralized and Volume Procurement of Drugs."

　　It clearly states that, in accordance with the principles of basic and clinical protection, the focus is to include drugs with large amounts and high purchase amounts in the basic medical insurance drug catalogue into the procurement scope, and gradually cover all kinds of clinically necessary and reliable drugs on the domestic market. It should be full.

　　In addition, the document also emphasizes that drugs that have passed (including deemed passing, the same below) the quality and efficacy consistency evaluation (hereinafter referred to as the consistency evaluation) of generic drugs shall be included in the procurement scope.

If the qualified drugs reach a certain quantity or amount, the centralized procurement will be initiated.

Actively explore suitable procurement methods for "orphan drugs" and shortage drugs to promote stable supply.

　　This means that in the future, it is a foregone conclusion that more types and therapeutic fields of drugs will be included in the national centralized drug procurement, and the people's "drug price list" will continue to expand.

　　For pharmaceutical companies, especially for domestic generic drug companies, centralized procurement is more like a watershed in industry reshuffle.

　　Fu Gang, vice president of the China Pharmaceutical Business Association, analyzed the media that if it is a generic drug, there is no certain market scale, the company itself does not have an international layout, and the domestic centralized procurement has not won the bid, and there is no such first patient in the hospital. The opportunity of prescription, business development will be more difficult.

　　"The decentralized structure of thousands of pharmaceutical companies is also immature for the entire industry, and there will be an integration process." Fu Gang analyzed that domestic generic drug companies will experience "merging similar items", and some powerful companies Winning, the industry gradually matures, which is beneficial to market supervision and industrial ecology.

(Finish)